Intellia Thera CS (NTLA)

$12.12 +0.63 (5.48%)
Market Cap 1.19B
Revenue (ttm) 57.88M
Net Income (ttm) -519.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -896.72%
Debt to Equity Ratio 0.00
Volume 3,421,900
Avg Vol 5,240,428
Day's Range N/A - N/A
Shares Out 103.58M
Stochastic %K 9%
Beta 2.31
Analysts Strong Sell
Price Target $36.71

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 6200
Address:
40 Erie Street, Suite 130, Cambridge, United States
TXBeanCounter
TXBeanCounter Aug. 4 at 7:25 PM
$NTLA $PGNY What do steady hands look like? 🙌
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 3:46 PM
$NTLA
0 · Reply
Morty752
Morty752 Aug. 4 at 3:41 PM
$NTLA I see the day this will touch its 2021 high. Just give it time.
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 2:30 PM
$NTLA 😘
0 · Reply
sogenerous
sogenerous Aug. 4 at 2:22 PM
$NTLA 60-90 is doable with good trial news and cuts
3 · Reply
sogenerous
sogenerous Aug. 4 at 2:20 PM
$NTLA still long here and like the chart and story
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 11:46 AM
$NTLA 😘😘
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 3:25 AM
$NTLA pick me up @ $11.51
0 · Reply
Bwill15
Bwill15 Aug. 3 at 11:18 PM
$NTLA price drop for an upcoming earnings beat on cost savings. $12.50 short term back to rock and roll. Another surprise random news to bring us up around $14 by September. Have some faith in our gang. The tech and the data so far is superior. No questions asked. Diamond hands 🙌
0 · Reply
360sage
360sage Aug. 3 at 11:09 PM
$NTLA
0 · Reply
Latest News on NTLA
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 7:30 AM EDT - 3 days ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 31, 2025, 7:30 AM EDT - 4 days ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 5 days ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jul 18, 2025, 8:00 AM EDT - 17 days ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 15, 2025, 10:45 AM EDT - 7 weeks ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 29, 2025, 11:25 AM EDT - 2 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 2 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 18, 2025, 7:25 AM EDT - 2 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 1:57 PM EDT - 2 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 12, 2025, 9:07 AM EDT - 3 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:37 AM EDT - 3 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 3 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

May 1, 2025, 7:30 AM EDT - 3 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 3 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 4 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 10, 2025, 10:40 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 1:03 PM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Apr 3, 2025, 7:30 AM EDT - 4 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Mar 28, 2025, 6:24 AM EDT - 4 months ago

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Mar 26, 2025, 7:30 AM EDT - 4 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 11, 2025, 5:43 PM EDT - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

Mar 10, 2025, 6:03 PM EDT - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA

Mar 6, 2025, 5:45 AM EST - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA

Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress

Mar 2, 2025, 9:30 AM EST - 5 months ago

Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress

Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 12:30 PM EST - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Feb 27, 2025, 7:30 AM EST - 5 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Feb 26, 2025, 8:56 PM EST - 5 months ago

Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

TXBeanCounter
TXBeanCounter Aug. 4 at 7:25 PM
$NTLA $PGNY What do steady hands look like? 🙌
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 3:46 PM
$NTLA
0 · Reply
Morty752
Morty752 Aug. 4 at 3:41 PM
$NTLA I see the day this will touch its 2021 high. Just give it time.
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 2:30 PM
$NTLA 😘
0 · Reply
sogenerous
sogenerous Aug. 4 at 2:22 PM
$NTLA 60-90 is doable with good trial news and cuts
3 · Reply
sogenerous
sogenerous Aug. 4 at 2:20 PM
$NTLA still long here and like the chart and story
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 11:46 AM
$NTLA 😘😘
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 3:25 AM
$NTLA pick me up @ $11.51
0 · Reply
Bwill15
Bwill15 Aug. 3 at 11:18 PM
$NTLA price drop for an upcoming earnings beat on cost savings. $12.50 short term back to rock and roll. Another surprise random news to bring us up around $14 by September. Have some faith in our gang. The tech and the data so far is superior. No questions asked. Diamond hands 🙌
0 · Reply
360sage
360sage Aug. 3 at 11:09 PM
$NTLA
0 · Reply
TheRealJayPowell
TheRealJayPowell Aug. 1 at 8:15 PM
$NTLA It is a race to the bottom!
0 · Reply
Tumble51
Tumble51 Aug. 1 at 5:11 PM
$AGIO Good wholesome senior execs win out ALNY RYTM Misfits lose $CADL $NTLA $AGIO $BLUE $REPL
0 · Reply
angelinvesting369
angelinvesting369 Aug. 1 at 5:02 PM
$NTLA long-term hold https://www.biopharmadive.com/news/alnylam-amvuttra-q2-2025-sales-ttr-cardiomyopathy-guidance/756477/
0 · Reply
karnak71
karnak71 Aug. 1 at 4:54 PM
$NTLA still a distance to fill to the 50 day. Hope for a bounce at that point.
0 · Reply
StockMarketGuru
StockMarketGuru Aug. 1 at 4:24 PM
$NTLA
0 · Reply
Tumble51
Tumble51 Aug. 1 at 3:00 PM
$NTLA $CADL ..not salty …just facts these two companies have CEO’s that are pathetic and the stock reflects that . Money is money and these two buffoon CEO , are Dr , and suck at being business men !!! KYMR has no product but a scientist as a CEO and in phase 1b and $40, not phase 3 and done , hahahaha
0 · Reply
Tumble51
Tumble51 Aug. 1 at 1:37 PM
$CADL $NTLA ..pros don’t even do that , lol Money sitting doing nothing isn’t their game They wait and pay up.. Look at Palantir !!!! They waited and climbed in at $20 You are a novice
1 · Reply
Farorm
Farorm Aug. 1 at 1:04 PM
$NTLA my guess red to green today. Weak jobs report so rates coming down should benefit biotechs.
0 · Reply
Tumble51
Tumble51 Aug. 1 at 1:01 PM
$NTLA well ..sorry to say ..back to $7 !! That’s your support , lovers of Leonard !! Dr.s suck at being CEO !!! …Schenkien was too ! $AGIO
1 · Reply
APman
APman Aug. 1 at 12:23 PM
$NTLA Had to buy more. No conviction on anything else but CRSP.
0 · Reply
TheRealJayPowell
TheRealJayPowell Aug. 1 at 10:23 AM
$NTLA The stock has no supports. It blew past any of the so called supports like it is fire free falling. Hedge funds doing what they do best. Short the stock force company to burn more cash and go bankrupt with no product. The FDA is run by big pharmaceutical who controls the approvals, CRLs, and denials. Gene editing is over.
1 · Reply
WhysoSerious93
WhysoSerious93 Aug. 1 at 8:38 AM
$NTLA back to single digits I guess
1 · Reply